BancorpSouth Bank Reduces Stake in Eli Lilly And Co (LLY)

BancorpSouth Bank decreased its holdings in shares of Eli Lilly And Co (NYSE:LLY) by 12.3% in the first quarter, HoldingsChannel reports. The institutional investor owned 1,923 shares of the company’s stock after selling 270 shares during the quarter. BancorpSouth Bank’s holdings in Eli Lilly And Co were worth $250,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Athena Capital Advisors LLC acquired a new position in shares of Eli Lilly And Co during the 4th quarter valued at about $26,000. Wakefield Asset Management LLLP acquired a new position in shares of Eli Lilly And Co during the 4th quarter valued at about $27,000. Larson Financial Group LLC acquired a new position in shares of Eli Lilly And Co during the 4th quarter valued at about $29,000. Ironwood Financial llc acquired a new position in shares of Eli Lilly And Co during the 4th quarter valued at about $30,000. Finally, Trust Department MB Financial Bank N A boosted its position in shares of Eli Lilly And Co by 54.7% during the 1st quarter. Trust Department MB Financial Bank N A now owns 232 shares of the company’s stock valued at $30,000 after acquiring an additional 82 shares during the last quarter. 84.49% of the stock is owned by institutional investors and hedge funds.

Several research analysts have recently weighed in on LLY shares. UBS Group lowered their price target on shares of Eli Lilly And Co from $107.53 to $100.00 and set an “average” rating on the stock in a research report on Friday, February 8th. Barclays reaffirmed a “buy” rating and issued a $140.00 target price on shares of Eli Lilly And Co in a research report on Sunday, April 14th. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Eli Lilly And Co in a research report on Monday, February 4th. Zacks Investment Research raised shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $142.00 target price on the stock in a research report on Wednesday, April 10th. Finally, Edward Jones raised shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $117.49 target price on the stock in a research report on Tuesday, April 23rd. Ten investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Eli Lilly And Co has a consensus rating of “Buy” and an average price target of $118.15.

In other news, SVP Aarti S. Shah sold 1,800 shares of the stock in a transaction dated Friday, April 5th. The shares were sold at an average price of $125.85, for a total transaction of $226,530.00. Following the sale, the senior vice president now owns 18,425 shares of the company’s stock, valued at $2,318,786.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Alfonso G. Zulueta sold 10,000 shares of the stock in a transaction dated Friday, April 12th. The stock was sold at an average price of $124.65, for a total transaction of $1,246,500.00. Following the sale, the senior vice president now directly owns 57,806 shares in the company, valued at approximately $7,205,517.90. The disclosure for this sale can be found here. Insiders have sold 845,959 shares of company stock worth $106,647,752 in the last three months. Corporate insiders own 0.11% of the company’s stock.

NYSE LLY opened at $116.01 on Friday. Eli Lilly And Co has a 12 month low of $81.49 and a 12 month high of $132.13. The company has a debt-to-equity ratio of 5.50, a quick ratio of 0.85 and a current ratio of 1.12. The stock has a market capitalization of $113.33 billion, a price-to-earnings ratio of 20.90, a P/E/G ratio of 2.07 and a beta of 0.27.

Eli Lilly And Co (NYSE:LLY) last posted its earnings results on Tuesday, April 30th. The company reported $1.33 EPS for the quarter, beating the Zacks’ consensus estimate of $1.32 by $0.01. Eli Lilly And Co had a net margin of 26.13% and a return on equity of 56.62%. The company had revenue of $5.09 billion for the quarter, compared to analysts’ expectations of $5.12 billion. During the same quarter in the prior year, the company posted $1.31 earnings per share. Eli Lilly And Co’s revenue for the quarter was up 2.6% compared to the same quarter last year. As a group, analysts predict that Eli Lilly And Co will post 5.66 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 10th. Stockholders of record on Friday, May 17th will be given a dividend of $0.645 per share. The ex-dividend date is Thursday, May 16th. This represents a $2.58 annualized dividend and a dividend yield of 2.22%. Eli Lilly And Co’s dividend payout ratio is presently 46.49%.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this report on another publication, it was illegally copied and republished in violation of U.S. & international copyright law. The original version of this report can be read at https://www.baseballdailydigest.com/news/2019/05/19/bancorpsouth-bank-reduces-stake-in-eli-lilly-and-co-lly.html.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Further Reading: Straddles

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.